Evidence map›Paper›PMID 28660149›Full record

ReviewJournal of clinical and translational hepatology2017

Mechanisms and Prevention of Vertical Transmission in Chronic Viral Hepatitis.

Marianna G Mavilia, George Y Wu

Open access · diamondAbstract readReview
In one paragraph

Review in Journal of clinical and translational hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Seroinfection of Antibodies toInfectious diseases in obstetrics and gynecology · 2024
    Article
  10. Review
  11. Spontaneous Clearance of Vertically Acquired Hepatitis C Infection: Implications for Testing and Treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  12. Article
  13. [The effect of maternal HBV DNA levels on HBV intrauterine transmission and fetal distress].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
  14. Review
  15. Treatment and prevention of viral hepatitis in pregnancy.American journal of obstetrics and gynecology · 2022
    Review
  16. Article
  17. Article
  18. Stillbirth and fetal capillary infection by SARS-CoV-2.American journal of obstetrics & gynecology MFM · 2022
    Article
  19. Article
  20. Viral Infections During Pregnancy: The Big Challenge Threatening Maternal and Fetal Health.Maternal-fetal medicine (Wolters Kluwer Health, Inc.) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Marianna G MaviliaDepartment of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, USA.
George Y WuDepartment of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, USA.
UConn Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vertical transmission (VT) is the primary route of transmission of viral hepatitis in children. The rate of VT ranges from 1-28% with hepatitis B virus (HBV) and 3-15% with hepatitis C virus (HCV). VT for both viruses can occur during the intrauterine or peripartum period. VT of HBV primarily occurs by intrauterine transmission (IUT). Hepatitis B surface antigen is unable to cross the placenta and, therefore, relies on processes like transplacental leakage, placental infection, cellular transmission by peripheral blood mononuclear cells, and germline transmission. HCV can also infect the fetus by IUT. Both viruses also have the potential for transmission during delivery, when there is increase chance of maternal-fetal blood exposure. HBV and HCV share some common risk factors for VT, including maternal viral load, human immunodeficiency virus co-infection and neonatal sex. Prevention of VT differs greatly between HBV and HCV. There are several alternatives for prevention of HBV VT, including antiviral medications during the third trimester of pregnancy and HBV vaccine, as well as hepatitis B immunoglobulin administration to infants post-partum. In contrast, there are no preventative interventions available for HCV. Despite these differences, the key to prevention with both viruses is screening women prior to and during pregnancy.

Indexed as

Hepatitis BHepatitis CMechanismsPreventionVertical transmission

Identifiers

PMID28660149
PMCPMC5472932
OpenAlexW2621830658

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.